James B Dale

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2327756/publications.pdf

Version: 2024-02-01

126	7,444	46918	62479
papers	citations	47 h-index	80 g-index

130	130	130	3230
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers. Clinical Infectious Diseases, 2005, 41, 1114-1122.	2.9	271
2	Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection. Cell, 2018, 173, 1083-1097.e22.	13.5	265
3	A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine Development. Journal of Infectious Diseases, 2014, 210, 1325-1338.	1.9	257
4	Epitopes of streptococcal M proteins shared with cardiac myosin.. Journal of Experimental Medicine, 1985, 162, 583-591.	4.2	222
5	Immunogenicity of a 26-Valent Group A Streptococcal Vaccine. Infection and Immunity, 2002, 70, 2171-2177.	1.0	221
6	New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine, 2011, 29, 8175-8178.	1.7	219
7	Type-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein. Nature, 1981, 292, 457-459.	13.7	194
8	Prevalence of Rheumatic Heart Disease in Children and Young Adults in Nicaragua. American Journal of Cardiology, 2010, 105, 1809-1814.	0.7	165
9	Multiple, heart-cross-reactive epitopes of streptococcal M proteins.. Journal of Experimental Medicine, 1985, 161, 113-122.	4.2	161
10	Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infection and Immunity, 1996, 64, 1495-1501.	1.0	159
11	Cloning, sequencing, and expression of a fibronectin/fibrinogen-binding protein from group A streptococci. Infection and Immunity, 1994, 62, 3937-3946.	1.0	152
12	Streptococcal C5a peptidase is a highly specific endopeptidase. Infection and Immunity, 1992, 60, 5219-5223.	1.0	151
13	Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci. Annals of Medicine, 2002, 34, 77-87.	1.5	150
14	Safety and Immunogenicity of a Recombinant Multivalent Group A Streptococcal Vaccine in Healthy Adults. JAMA - Journal of the American Medical Association, 2004, 292, 709.	3.8	144
15	Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. Journal of Immunology, 1993, 151, 2820-8.	0.4	133
16	Protective antigenic determinant of streptococcal M protein shared with sarcolemmal membrane protein of human heart.. Journal of Experimental Medicine, 1982, 156, 1165-1176.	4.2	132
17	Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. Journal of Immunology, 1989, 143, 2677-83.	0.4	128
18	Group A Streptococcal Pharyngitis Serotype Surveillance in North America, 2000â€“2002. Clinical Infectious Diseases, 2004, 39, 325-332.	2.9	115

#	Article	IF	Citations
19	Sequence of myosin-crossreactive epitopes of streptococcal M protein.. Journal of Experimental Medicine, 1986, 164, 1785-1790.	4.2	113
20	Status of research and development of vaccines for Streptococcus pyogenes. Vaccine, 2016, 34, 2953-2958.	1.7	113
21	Serum opacity factor is a major fibronectin-binding protein and a virulence determinant of M type 2 Streptococcus pyogenes. Molecular Microbiology, 1999, 32, 89-98.	1.2	109
22	Temporal Changes in Streptococcal M Protein Types and the Near-Disappearance of Acute Rheumatic Fever in the United States. Clinical Infectious Diseases, 2006, 42, 441-447.	2.9	108
23	Differential effects of the streptococcal fibronectin-binding protein, FBP54, on adhesion of group A streptococci to human buccal cells and HEp-2 tissue culture cells. Infection and Immunity, 1996, 64, 2415-2419.	1.0	104
24	Sevenâ€Year Surveillance of North American Pediatric Group A Streptococcal Pharyngitis Isolates. Clinical Infectious Diseases, 2009, 49, 78-84.	2.9	97
25	Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. Vaccine, 1999, 17, 193-200.	1.7	91
26	Prospects for a Group A Streptococcal Vaccine: Rationale, Feasibility, and Obstacles--Report of a National Institute of Allergy and Infectious Diseases Workshop. Clinical Infectious Diseases, 2005, 41, 1150-1156.	2.9	91
27	Relationship between Expression of the Family of M Proteins and Lipoteichoic Acid to Hydrophobicity and Biofilm Formation in Streptococcus pyogenes. PLoS ONE, 2009, 4, e4166.	1.1	88
28	Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine, 2013, 31, 1576-1581.	1.7	82
29	Group A streptococcal vaccines: Paving a path for accelerated development. Vaccine, 2013, 31, B216-B222.	1.7	79
30	Identification of a Gene within a Pathogenicity Island of Enterotoxigenic Escherichia coli H10407 Required for Maximal Secretion of the Heat-Labile Enterotoxin. Infection and Immunity, 2000, 68, 2766-2774.	1.0	77
31	Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein.. Journal of Experimental Medicine, 1986, 163, 1191-1202.	4.2	76
32	Intranasal Immunization with Multivalent Group A Streptococcal Vaccines Protects Mice against Intranasal Challenge Infections. Infection and Immunity, 2004, 72, 2507-2512.	1.0	76
33	The Importance of the Group AStreptococcusCapsule in the Pathogenesis of Human Infections: A Historical Perspective. Clinical Infectious Diseases, 2008, 46, 1038-1045.	2.9	75
34	Lipoteichoic acid and M protein: dual adhesins of group A streptococci. Microbial Pathogenesis, 1992, 12, 199-208.	1.3	74
35	Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein.. Journal of Experimental Medicine, 1983, 158, 1727-1732.	4.2	73
36	Common protective antigens of group A streptococcal M proteins masked by fibrinogen.. Journal of Experimental Medicine, 1984, 159, 1201-1212.	4.2	73

#	Article	IF	Citations
37	Recombinant, octavalent group A streptococcal M protein vaccine. Vaccine, 1996, 14, 944-948.	1.7	71
38	Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein. Molecular Microbiology, 2006, 59, 936-947.	1.2	71
39	Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. Journal of Immunology, 1992, 148, 888-93.	0.4	69
40	The Reemergence of Serious Group A Streptococcal Infections and Acute Rheumatic Fever. American Journal of the Medical Sciences, 1996, 311, 41-54.	0.4	66
41	Analysis of the role of M24 protein in group A streptococcal adhesion and colonization by use of omega-interposon mutagenesis. Infection and Immunity, 1994, 62, 4868-4873.	1.0	63
42	New protective antigen of group A streptococci. Journal of Clinical Investigation, 1999, 103, 1261-1268.	3.9	58
43	Comparison of the leader sequences of four group A streptococcal M protein genes. Nucleic Acids Research, 1988, 16, 4667-4677.	6.5	57
44	Serum Opacity Factor (SOF) of Streptococcus pyogenes Evokes Antibodies That Opsonize Homologous and Heterologous SOF-Positive Serotypes of Group A Streptococci. Infection and Immunity, 2003, 71, 5097-5103.	1.0	56
45	Update on group A streptococcal vaccine development. Current Opinion in Infectious Diseases, 2020, 33, 244-250.	1.3	56
46	Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study. Vaccine, 2020, 38, 1384-1392.	1.7	53
47	Protective immunogenicity and T lymphocyte specificity of a trivalent hybrid peptide containing NH2-terminal sequences of types 5, 6, and 24 M proteins synthesized in tandem.. Journal of Experimental Medicine, 1987, 166, 647-656.	4.2	52
48	Protective and heart-crossreactive epitopes located within the NH2 terminus of type 19 streptococcal M protein.. Journal of Experimental Medicine, 1988, 167, 1849-1859.	4.2	51
49	Opsonic Antibodies to the Surface M Protein of Group A Streptococci in Pooled Normal Immunoglobulins (IVIG): Potential Impact on the Clinical Efficacy of IVIG Therapy for Severe Invasive Group A Streptococcal Infections. Infection and Immunity, 1998, 66, 2279-2283.	1.0	51
50	Epitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium. Journal of Immunology, 1991, 146, 3132-7.	0.4	50
51	Passive Protection of Mice against Group A Streptococcal Pharyngeal Infection by Lipoteichoic Acid. Journal of Infectious Diseases, 1994, 169, 319-323.	1.9	49
52	Multivalent Group A Streptococcal Vaccine Elicits Bactericidal Antibodies against Variant M Subtypes. Vaccine Journal, 2005, 12, 833-836.	3.2	48
53	Recombinant tetravalent group A streptococcal M protein vaccine. Journal of Immunology, 1993, 151, 2188-94.	0.4	48
54	Hybridoma antibodies against protective and nonprotective antigenic determinants of a structurally defined polypeptide fragment of streptococcal M protein.. Journal of Experimental Medicine, 1982, 155, 1010-1018.	4.2	47

#	Article	IF	Citations
55	Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci. Journal of the Pediatric Infectious Diseases Society, 2017, 6, 187-196.	0.6	47
56	Sequence of protective epitopes of streptococcal M proteins shared with cardiac sarcolemmal membranes. Journal of Immunology, 1987, 139, 1285-90.	0.4	47
57	Current Status of Group A Streptococcal Vaccine Development. Advances in Experimental Medicine and Biology, 2008, 609, 53-63.	0.8	46
58	Repeating covalent structure and protective immunogenicity of native and synthetic polypeptide fragments of type 24 streptococcal M protein. Mapping of protective and nonprotective epitopes with monoclonal antibodies.. Journal of Biological Chemistry, 1983, 258, 13250-13257.	1.6	46
59	Protective and autoimmune epitopes of streptococcal M proteins. Vaccine, 1988, 6, 192-196.	1.7	45
60	Intranasal Immunization with Recombinant Group A Streptococcal M Protein Fragment Fused to the B Subunit of Escherichia coli Labile Toxin Protects Mice against Systemic Challenge Infections. Journal of Infectious Diseases, 1995, 171, 1038-1041.	1.9	45
61	Immune Cross-Opsonization Withinemm Clusters Following Group AStreptococcus Skin Infection: Broadening the Scope of Type-Specific Immunity. Clinical Infectious Diseases, 2017, 65, 1523-1531.	2.9	45
62	Heterogeneity of type-specific and cross-reactive antigenic determinants within a single M protein of group A streptococci.. Journal of Experimental Medicine, 1980, 151, 1026-1038.	4.2	43
63	The Reemergence of Serious Group A Streptococcal Infections and Acute Rheumatic Fever. American Journal of the Medical Sciences, 1996, 311, 41-54.	0.4	42
64	Structure-based design of broadly protective group a streptococcal M protein-based vaccines. Vaccine, 2017, 35, 19-26.	1.7	41
65	Repeating covalent structure and protective immunogenicity of native and synthetic polypeptide fragments of type 24 streptococcal M protein. Mapping of protective and nonprotective epitopes with monoclonal antibodies. Journal of Biological Chemistry, 1983, 258, 13250-7.	1.6	41
66	Added Value of the emm-Cluster Typing System to Analyze Group A Streptococcus Epidemiology in High-Income Settings. Clinical Infectious Diseases, 2014, 59, 1651-1652.	2.9	40
67	Human cytotoxic T lymphocytes evoked by group A streptococcal M proteins.. Journal of Experimental Medicine, 1987, 166, 1825-1835.	4.2	39
68	A 28-kilodalton fibronectin-binding protein of group a streptococci. Current Microbiology, 1992, 25, 245-250.	1.0	39
69	Inactivation of DltA Modulates Virulence Factor Expression in Streptococcus pyogenes. PLoS ONE, 2009, 4, e5366.	1.1	39
70	Progress Toward a Global Group A Streptococcal Vaccine. Pediatric Infectious Disease Journal, 2013, 32, 180-182.	1.1	38
71	Conversion of M serotype 24 of Streptococcus pyogenes to M serotypes 5 and 18: effect on resistance to phagocytosis and adhesion to host cells. Infection and Immunity, 1997, 65, 2472-2474.	1.0	37
72	Attachment of Streptococcus pyogenes to Mammalian Cells. Clinical Infectious Diseases, 1983, 5, S670-S677.	2.9	36

#	Article	IF	Citations
73	Antibodies against a Synthetic Peptide of SagA Neutralize the Cytolytic Activity of Streptolysin S from Group A Streptococci. Infection and Immunity, 2002, 70, 2166-2170.	1.0	36
74	Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes. Vaccine, 2010, 28, 5017-5022.	1.7	36
75	Monoclonal antibody to human renal glomeruli cross-reacts with streptococcal M protein. Infection and Immunity, 1987, 55, 2416-2419.	1.0	36
76	Blastogenic responses of human lymphocytes to structurally defined polypeptide fragments of streptococcal M protein. Journal of Immunology, 1981, 126, 1499-505.	0.4	36
77	Group A Streptococcal emm Type Prevalence Among Symptomatic Children in Cape Town and Potential Vaccine Coverage. Pediatric Infectious Disease Journal, 2014, 33, 208-210.	1.1	33
78	Sequence and type-specific immunogenicity of the amino-terminal region of type 1 streptococcal M protein. Journal of Immunology, 1987, 139, 3084-90.	0.4	33
79	Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study. Vaccine, 2019, 37, 3485-3494.	1.7	31
80	Progress in Group A Streptococcal Vaccine Development. Pediatric Infectious Disease Journal, 2004, 23, 765-766.	1.1	30
81	The American Heart Associationâ€™s Call to Action for Reducing the Global Burden of Rheumatic Heart Disease: A Policy Statement From the American Heart Association. Circulation, 2020, 142, e358-e368.	1.6	30
82	Spa Contributes to the Virulence of Type 18 Group A Streptococci. Infection and Immunity, 2001, 69, 2943-2949.	1.0	29
83	Mapping the Fibrinogen-Binding Domain of Serum Opacity Factor of Group A Streptococci. Current Microbiology, 2002, 44, 236-240.	1.0	29
84	A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study. Lancet Microbe, The, 2021, 2, e291-e299.	3.4	29
85	Unique and common protective epitopes among different serotypes of group A streptococcal M proteins defined with hybridoma antibodies. Infection and Immunity, 1984, 46, 267-269.	1.0	26
86	Protective immunity evoked by locally administered group A streptococcal vaccines in mice. Journal of Immunology, 1988, 141, 2767-70.	0.4	24
87	Comparison of adherence to and penetration of a human laryngeal epithelial cell line by group A streptococci of various M protein types. FEMS Immunology and Medical Microbiology, 1999, 23, 195-204.	2.7	23
88	GROUP A STREPTOCOCCAL VACCINES. Infectious Disease Clinics of North America, 1999, 13, 227-243.	1.9	23
89	Type-specific antibodies to structurally defined fragments of streptococcal M proteins in patients with acute rheumatic fever. Infection and Immunity, 1982, 38, 573-579.	1.0	22
90	Prevalence of group A Î²-hemolytic streptococcal throat carriage and prospective pilot surveillance of streptococcal sore throat in Ugandan school children. International Journal of Infectious Diseases, 2020, 93, 245-251.	1.5	21

#	Article	IF	Citations
91	Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus:S. pyogenes super-infection. Vaccine, 2014, 32, 5241-5249.	1.7	20
92	Expression of protective and cardiac tissue cross-reactive epitopes of type 5 streptococcal M protein in Escherichia coli. Infection and Immunity, 1985, 48, 198-203.	1.0	20
93	A double-blind, randomized phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults. International Congress Series, 2006, 1289, 303-306.	0.2	19
94	Streptococcal Pharyngitis in Schoolchildren in Bamako, Mali. Pediatric Infectious Disease Journal, 2015, 34, 463-468.	1.1	19
95	Protective Immunogenicity of Group A Streptococcal M-Related Proteins. Vaccine Journal, 2015, 22, 344-350.	3.2	18
96	Trivalent M-related protein as a component of next generation group A streptococcal vaccines. Clinical and Experimental Vaccine Research, 2017, 6, 45.	1.1	18
97	The Cape Town Clinical Decision Rule for Streptococcal Pharyngitis in Children. Pediatric Infectious Disease Journal, 2017, 36, 250-255.	1.1	16
98	Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies againstStreptococcus pyogenes. MSphere, 2018, 3, .	1.3	16
99	Rationale and design of the African group A streptococcal infection registry: the AFROStrepstudy. BMJ Open, 2016, 6, e010248.	0.8	13
100	Systematic Review and Meta-analysis of the Prevalence of Group A Streptococcal emm Clusters in Africa To Inform Vaccine Development. MSphere, 2020, 5, .	1.3	11
101	Dynamic epidemiology of group A streptococcal serotypes. Lancet, The, 2002, 359, 889.	6.3	10
102	Streptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 51-57.	1.3	9
103	Design of Broadly Cross-Reactive M Proteinâ€"Based Group A Streptococcal Vaccines. Journal of Immunology, 2021, 207, 1138-1149.	0.4	9
104	A Novel Live Vector Group A StreptococcalemmType 9 Vaccine Delivered Intranasally Protects Mice against Challenge Infection withemmType 9 Group A Streptococci. Vaccine Journal, 2014, 21, 1343-1349.	3.2	8
105	One More Disguise in the Stealth Behavior of Streptococcus pyogenes. MBio, 2016, 7, .	1.8	8
106	Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M proteinâ€"derived peptides. Journal of Biological Chemistry, 2020, 295, 3826-3836.	1.6	8
107	Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town. MSphere, 2019, 4, .	1.3	7
108	The NH₂â€Terminal Region ofStreptococcus pyogenesM5 Protein Confers Protection against Degradation by Proteases and Enhances Mucosal Colonization of Mice. Journal of Infectious Diseases, 2010, 201, 1580-1588.	1.9	6

#	Article	IF	Citations
109	Group A Streptococcus Expresses a Trio of Surface Proteins Containing Protective Epitopes. Vaccine Journal, 2014, 21, 1421-1425.	3.2	6
110	Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent Mâ€protein antigens derived from Group A Streptococcus. Microbiology and Immunology, 2018, 62, 395-404.	0.7	6
111	Age-associated differences in prevalence of group A streptococcal type-specific M antibodies in children. European Journal of Pediatrics, 2009, 168, 679-683.	1.3	5
112	Progress in the Development of Effective Vaccines to Prevent Selected Gram-Positive Bacterial Infections. American Journal of the Medical Sciences, 2010, 340, 218-225.	0.4	5
113	Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an antiâ€streptococcal vaccine. Microbiology and Immunology, 2018, 62, 711-719.	0.7	5
114	Group A Streptococcal Vaccines. Pediatric Annals, 1998, 27, 301-308.	0.3	5
115	Protective antibody against a peptide fragment of type 5 streptococcal M protein cross-reacts with human heart tissue. Transactions of the Association of American Physicians, 1982, 95, 286-91.	0.1	5
116	Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes. Vaccine, 2021, 39, 1773-1779.	1.7	4
117	Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection. PLoS ONE, 2020, 15, e0235139.	1.1	3
118	Group A Streptococcal Virulence: New Lessons. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 160-161.	0.6	2
119	Utility of Human Immune Responses to GAS Antigens as a Diagnostic Indicator for ARF: A Systematic Review. Frontiers in Cardiovascular Medicine, 2021, 8, 691646.	1.1	2
120	Five-year group A streptococcal pharyngitis serotype surveillance in North America, 2000â€“2005. International Congress Series, 2006, 1289, 30-33.	0.2	1
121	Why acute rheumatic fever has virtually disappeared in the U.S.. International Congress Series, 2006, 1289, 285-288.	0.2	1
122	Structure-Function Analysis of Group A Streptococcal M Proteins with Hybridoma Antibodies. , 1985, , 1-21.		1
123	Phosphorylase-cross-reactive antibodies evoked by streptococcal M protein. Infection and Immunity, 1990, 58, 774-778.	1.0	1
124	Southern Society for Clinical Investigation Foundersâ€™ Medal Recipientâ€™s Address. American Journal of the Medical Sciences, 2002, 324, 61-62.	0.4	0
125	Macrolide resistance among pediatric pharyngeal Group A streptococci is high in Canada and increasing in the US. International Congress Series, 2006, 1289, 95-98.	0.2	0
126	Role of the Mga regulon in the resistance of M type 4 Streptococcus pyogenes to phagocytosis. International Congress Series, 2006, 1289, 195-198.	0.2	0